• Product nameAnti-Ras antibody [Y13-259]
    See all Ras primary antibodies
  • Description
    Rat monoclonal [Y13-259] to Ras
  • Specificityab79973 is against the p21 transforming protein encoded by the v-ras and c-ras (ras) oncogenes and reacts with both the Harvey (Ha-ras) and Kirsten (Ki-ras) p21 proteins.
  • Tested applicationsSuitable for: WB, IPmore details
  • Species reactivity
    Reacts with: Rat, Saccharomyces cerevisiae
    Predicted to work with: Mouse, Non Human Primates
  • Immunogen

    Syngeneic normal rat kidney cells (NRK) infected with Harvey murine sarcoma virus.

  • Positive control
    • Transformed NRK cells.



Our Abpromise guarantee covers the use of ab79973 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use at an assay dependent concentration.
IP Use at an assay dependent dilution.


  • FunctionRas proteins bind GDP/GTP and possess intrinsic GTPase activity.
  • Involvement in diseaseDefects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
    Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
    Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
    Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
    Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
    Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).
  • Sequence similaritiesBelongs to the small GTPase superfamily. Ras family.
  • Post-translational
    Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
    S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.
  • Cellular localizationCell membrane. Golgi apparatus membrane. The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus.
  • Information by UniProt
  • Database links
  • Alternative names
    • C-BAS/HAS antibody
    • c-H-ras antibody
    • C-HA-RAS1 antibody
    • CTLO antibody
    • GTPase HRas antibody
    • GTPase KRas antibody
    • GTPase NRas antibody
    • H-Ras-1 antibody
    • H-RASIDX antibody
    • Ha-Ras antibody
    • HAMSV antibody
    • HRAS antibody
    • HRAS1 antibody
    • K RAS2A antibody
    • K RAS2B antibody
    • K RAS4A antibody
    • K RAS4B antibody
    • K-RAS antibody
    • KRAS antibody
    • KRAS1 antibody
    • KRAS2 antibody
    • N-RAS antibody
    • N-terminally processed antibody
    • NRAS antibody
    • NRAS1 antibody
    • p21ras antibody
    • RASH_HUMAN antibody
    • RASH1 antibody
    • RASK2 antibody
    • Transforming protein p21 antibody
    • v Ha ras Harvey rat sarcoma viral oncogene homolog antibody
    • v Ki ras2 Kirsten rat sarcoma viral oncogene homolog antibody
    • v ras neuroblastoma RAS viral oncogene homolog antibody
    see all

Anti-Ras antibody [Y13-259] images

  • Immunoprecipitation of Ras from transformed NRK cells. NRK rat fibroblasts and clonal derivatives transformed by Ha-MuSV and Ki-MuSV were metabolically lableled with [35S]methionine and lysates were subjected to immunoprecipitaion. ab79973 was added at 5µl of a 10-fold concentrate of spent culture medium prepared by ammonium sulphate precipitation. lane 1: Ha-MuSV NRK extracts immunoprecipitated with ab79973. lane 2: Ha-MuSV NRK extracts immunoprecipitated with control monoclonal antibody. lane 3: Ki-MuSV NRK extracts immunoprecipitated with ab79973. lane 3: Ki-MuSV NRK extracts immunoprecipitated with control monoclonal antibody

References for Anti-Ras antibody [Y13-259] (ab79973)

This product has been referenced in:
  • Furth ME  et al. Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family. J Virol 43:294-304 (1982). Read more (PubMed: 6287003) »

See 1 Publication for this product

Product Wall

Thank you very much for contacting us and sorry for the delay in getting back to you. I noe have more information relating to ab16881 and ab79973. Both of these antibodies are rat monoclonals directed against Ras, and whilst they are of the same cl...

Read More
Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Saccharomyces cerevisiae Cell lysate - whole cell (Yeast Mat a cell)
Loading amount 50 µg
Specification Yeast Mat a cell
Gel Running Conditions Reduced Denaturing (8% SDS-PAGE)
Blocking step Milk as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 24°C

Abcam user community

Verified customer

Submitted Jul 07 2011